secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001125345-25-000109
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics Q3 net income $16.8M on $72.8M revenue; ends lorigerlimab prostate study; secures $75M partnership payments
--------------------------------------------------------------------------------

- Net income $16.8M ($0.27 diluted EPS) vs $56.3M ($0.90) in Q3 2024; revenue $72.8M down from $110.7M.
- Discontinued lorigerlimab in prostate cancer (LORIKEET) after interim data; continues LINNET ovarian study, update by mid-2026.
- Received $75M in new partnership payments: $50M from Sanofi (TZIELD milestones), $25M from Gilead (new preclinical program).
- Cash $146.4M at Sep 30, expected to add $75M in Q4; runway extended into late 2027.
- Three ADC programs advancing: MGC026 started Phase 1 expansion, MGC028 in Phase 1 dose escalation, MGC030 IND planned 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534525000109/0001125345-25-000109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534525000109/mgnx-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001125345-25-000109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer